Farra IVI	· ·	440 Cubetitute	IIC Danaster	ent of Commons	Application Number	10/037 415	
			-	01 00		January 4, 2002	
					David Baltimore		
nieona	# A 7E	ION DICCI OCI		A TOTAL	Art Unit	1636	
_		ION DISCLOSU				D. Guzo	
Use seve	erai s	sheets if necessar	y)			75723-	
					Attorney Docket No.	ZB/JPW/GJG/CS	S
					•		
				LITERATURE DOC			T^2
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	1	litigation o Pharmaceutio	captioned Ar	on Chart, filengen Inc., et et al., U.S. CA No. 06-259	al. v. ARIA District Co	D	
	2	Deposition Transcript of Randolph Wall, Ph.D., pages 149-152, in the concurrent litigation captioned Amgen Inc., et al. v. ARIAD Pharmaceuticals, Inc., et al., U.S. District Court for the District of Delaware, CA No. 06-259(MPT);					
	3	Brief for Appellants, ARIAD, filed December 16, 2008 in the concurrent litigation captioned Amgen Inc., et al. v. ARIAD Pharmaceuticals, Inc., et al., U.S. Court of Appeals for the Federal Circuit, Docket No. 2009-1023;					
	4	Defendant Eli Lilly and Company's Motion in Limine to Exclude Adding Claim Limitations and Expert Testimony That Offers Construction of Claim Terms Inconsistent With the Court's Construction, filed February 24, 2006 in the concurrent litigation captioned ARIAD Pharmaceuticals, Inc., et al. v. Eli Lilly & Co., U.S. District Court for the District of Massachusetts, CA No. 02-CV-11280-RWZ;					
	5	2006, in the Pharmaceutic	concurrent cals, Inc., art for the	on Special Ve t litigation et al. v. El District of	captioned AR i Lilly & Co	IAD ., U.S.	
	6	filed Novemb captioned AF	per 12, 2008 R <i>IAD Pharmad</i> U.S. Court	nt-Appellant B in the conc ceuticals, In c of Appeals	urrent litig c., et al. v	ation . Eli Lilly	
EXAMINER		<u> </u>		DATE CONSIDERED			

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

DATE CONSIDERED

SIGNATURE

Applicants: David Baltimore, et al. Serial No.: 10/037,415 Filed: January 4, 2002

						Page 2 o) I 3	
Form P	rO-1	449 Substitute	U.S. Departme	ent of Commerce	Application Number	10/037,415		
_ C.III L _ C A777 DUDUHUU				Patent and Trademark Office		January 4, 20		
					First Named Inventor	David Baltimo	ore	
INFORM	ЛАТ	ION DISCLOSE	IRE STATEME	ENT	Art Unit	1636		
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Examiner Name	D. Guzo				
				Attorney Docket No.	75723-			
					Attorney Docket No.	ZB/JPW/GJG/CS	<u> </u>	
			NON PATENT	LITERATURE DOC	CUMENTS			
Examiner Initials*	Cite No. ¹	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,						
	7	Record Mater 23, 2008 in <i>Pharmaceutic</i>	tials From the the concurrence of the concurrence o	opellees, ARI the Joint App rent litigati et al. v. El ne Federal Ci	endix, filed on captioned i Lilly & Co	December ARIAD ., U.S.		
	8	From the Joi concurrent l Inc., et al.	Opposition to ARIAD's Motion to Strike Materials Joint Appendix, filed January 9, 2009 in the nt litigation captioned ARIAD Pharmaceuticals, al. v. Eli Lilly & Co., U.S. Court of Appeals for ral Circuit, Docket No. 2008-1248; Reply in Support of Motion to Strike Extra-Record s From the Joint Appendix, filed January 21, 2009 oncurrent litigation captioned ARIAD uticals, Inc., et al. v. Eli Lilly & Co., U.S. Appeals for the Federal Circuit, Docket No. 2008-					
	9	Materials Fr in the concu <i>Pharmaceutic</i>						
	10	Declaration	of Dr. Inde	er Verma, dat	ed November	9, 2006;		
	11	Second Decla 2007;	aration of I	Or. Inder Ver	ma, dated Oc	tober 19,		
	12	Final Office Reexaminatio	e Action iss on Control 1	sued October Nos. 90/007,5	16, 2008 in 03 and 90/00	Merged 7,828		
	13	of December Concurrent I	2, 2008 Exa Proceedings 2009 in Men	, 2008 Final aminer Interv Under 37 C.F rged Reexamin 328	riew, and Sta C.R. § 1.565,	tement of filed		
	14	Third Declar 2009.	ration of Di	r. Inder Verm	a, dated Jan	uary 26,		

EXAMINER
SIGNATURE
DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

Form PTO-1449 Substitute U.S. Department of Commerce Patent and Trademark Office			U.S. Departme	ent of Commerce	Application Number	10/037,415	
			•		Filing Date	January 4, 20	
				tor David Baltimor			
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) Art Unit 1636 Examiner Name D. Guzo 75723- Attorney Docket No. 75723-					1636		
					Examiner Name		
					Attorney Docket No.		, ,
						ZB/JPW/GJG/CS	
				LITERATURE DOC		- Т	T ²
Examiner Initials							
	15	Final Office U.S. Applica	Action iss	sued June 26, 0/037,341;	2008 in com	nection with	
	16	Response to June 26, 2008 Final Office Action, Petition For Three-Month Extension of Time and Supplemental Information Disclosure Statement, filed December 24, 2008 in U.S. Application No. 10/037,341; and					
	17	Notice of Ap Application	opeal, filed No. 10/037,	d December 24,	, 2008 in U.	s.	
EXAMINER SIGNATUR		<u> </u>		DATE CONSIDERED			

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.